Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NGL Fine-ChemNSE:NGLFINE -1.12%78 Debt-to-EBITDA is 1.28 as of Mar. 2026, which is 52% above its 10-year median of 0.84. GuruFocus rates NSE:NGLFINE with a GF Score™ of 78/100 and a GF Value™ of ₹2,852.22 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 681 Drug Manufacturers companies, NGL Fine-Chem ranks better than 54.04% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for NGL Fine-Chem's Debt-to-EBITDA or its related term are showing as below:
NSE:NGLFINE'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.19 Med: 0.84 Max: 1.83
Current: 1.4
During the past 13 years, the highest Debt-to-EBITDA Ratio of NGL Fine-Chem was 1.83. The lowest was 0.19. And the median was 0.84.
NSE:NGLFINE's Debt-to-EBITDA is ranked better than 54.04% of 681
companies
in the Drug Manufacturers industry
Industry Median: 1.63
vs NSE:NGLFINE: 1.40
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
NGL Fine-Chem Debt-to-EBITDA Related Terms
NGL Fine-Chem Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for NGL Fine-Chem's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:NGLFINE vs LLY, JNJ, ABBV: Debt-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, NGL Fine-Chem's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NGL Fine-Chem Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, NGL Fine-Chem's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where NGL Fine-Chem's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
NGL Fine-Chem (NSE:NGLFINE) has a Debt-to-EBITDA of 1.28 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on NGL Fine-Chem. This is 52% above median its historical median of 0.84. Over the past decade, NGL Fine-Chem's Debt-to-EBITDA has ranged from 0.19 to 1.83. According to the industry distribution chart, NGL Fine-Chem ranks #313 out of 681 companies in the Drug Manufacturers industry, placing it in the top 46%.
Is NGL Fine-Chem's Debt-to-EBITDA too high?
NGL Fine-Chem's current Debt-to-EBITDA of 1.28 is 52% above median its 10-year median of 0.84. Over the past 10 years, this metric has ranged from a low of 0.19 to a high of 1.83. The Drug Manufacturers industry median Debt-to-EBITDA is 1.63. NGL Fine-Chem's value of 1.28 is 21.5% below this industry median. Based on the distribution chart, NGL Fine-Chem ranks #313 out of 681 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, NGL Fine-Chem has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NGL Fine-Chem's Debt-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, NGL Fine-Chem ranks #313 out of 681 companies for Debt-to-EBITDA. This puts NGL Fine-Chem in the upper half of its industry. The industry median Debt-to-EBITDA is 1.63. NGL Fine-Chem's value of 1.28 is 21.5% below this benchmark. Historically, NGL Fine-Chem's own Debt-to-EBITDA has ranged from 0.19 to 1.83 over the past decade. While the company's 10-year median is 0.84 vs. the industry median of 1.63, NGL Fine-Chem has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.63, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NGL Fine-Chem's current Debt-to-EBITDA of 1.28 is 21.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on NGL Fine-Chem. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NGL Fine-Chem's current Debt-to-EBITDA is 1.28, which is 52% above median its own 10-year median of 0.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NGL Fine-Chem stock overvalued right now?
Based on GuruFocus' analysis, NGL Fine-Chem (NSE:NGLFINE) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,852.22, compared to a current price of ₹3,409.00 — trading 19.5% above its estimated fair value. The current Debt-to-EBITDA is 1.28, which is 52% above median its 10-year median of 0.84 and 21.5% below the Drug Manufacturers industry median of 1.63. NGL Fine-Chem's overall GF Score™ is 78/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For NGL Fine-Chem (NSE:NGLFINE), the current Debt-to-EBITDA is 1.28 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NGL Fine-Chem (NSE:NGLFINE) Overvalued in 2026?
Based on GuruFocus' analysis, NGL Fine-Chem stock appears to be overvalued.
The current stock price of ₹3,409.00 is trading 19.5% above its estimated GF Value™ of ₹2,852.22.
GuruFocus considers NGL Fine-Chem to be Modestly Overvalued.
Key valuation signals for NSE:NGLFINE:
Debt-to-EBITDA: 1.28 (52% above median its 10-year median of 0.84)
GF Value™: ₹2,852.22 vs. price of ₹3,409.00 (19.5% above fair value)
Industry Position: 21.5% below the Drug Manufacturers median (#313 of 681)
No single metric tells the full story. See the NSE:NGLFINE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NGL Fine-Chem Ltd is an Indian company engaged in the pharmaceutical business. It is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health, catering to various companies to custom-manufacture pharmaceuticals. The company's product portfolio comprises animal health APIs such as homidium chloride, nitroxynil, clorsulon, decoquinate, fenbendazole, etc.; human health APIs such as nitazoxanide and atovaquone; drug intermediates and specialty chemicals; and finished dosage forms such as diminazene aceturate granules and homidium chloride tablets. Geographically, the group generates maximum revenue from the Asia-Pacific region, and the rest from India, Europe, the USA, and the rest of the world.
78GF Score
Get the complete analysis for NSE:NGLFINE
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NGLFINE has been successfully added to your 
